Carl Goldfischer, MD, is an Advisor for Bay City Capital. He had previously served as Managing Director for the firm since 2000. He has invested across all subsectors within the life sciences industry and his expertise spans both private and public markets. In addition, he brings deep operational experience in finance, clinical trial development, and clinical medicine.
Dr. Goldfischer’s investments have included Cydan, EnteroMedics, Epizyme, MAP Pharmaceuticals, Nevro, Oculex Pharmaceuticals, PharmAkea, and SynGen.
Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of publicly traded biotech company ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Health Care Research Analyst with the Reliance Insurance Company and was a Director of Research at D. Blech & Co. He began his career as a radiation oncologist at Montefiore Hospital, part of the Albert Einstein College of Medicine. Dr. Goldfischer received an MD with honors in Scientific Research from Albert Einstein College of Medicine and a BA from Sarah Lawrence College.